Table 3.
Clinical information of discordant cases
| Result of EGFR mutation | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| No | Age | Sex | Sampling method | Histology | Oncomine Dx Target Test | PNA‐LNA PCR clamp | Stage (UICC‐eighth) | Treatment | Response to EGFR‐TKI |
| 1 | 47 | M | TBB | ADC | Negative | Detected exon 19 deletion | IVB | Osimertinib | PD |
| 2 | 70 | M | EBB | LCC | Negative | Detected exon 19 deletion | Postoperative recurrence | Osimertinib | NA due to pneumonitis |
| 3 | 68 | M | TBB | ADC | Negative | Detected exon 19 deletion | IA3 | Operation | Not administered |
| 4 | 68 | F | TBB | ADC | Negative | Detected exon 19 deletion | IB | Operation | Not administered |
ADC, adenocarcinoma; EBB, endobronchial biopsy; EGFR, epidermal growth factor receptor; LCC, large cell carcinoma; NA, not assessed; PD, progression disease; TBB, transbronchial biopsy; TKI, tyrosine kinase inhibitor; UICC, Union for International Cancer Control.